ANI purchases rights to Shire antibiotic

ANI Pharmaceuticals (NASDAQ:ANIP) acquires the U.S. rights to Shire's (NASDAQ:SHPG) Vancocin (vancomycin hydrochloride) 125 mg and 250 mg capsules plus the approved ANDAs for vancomycin hydrochloride injectable (500 my, 1 gm, 10 gm) and oral solution 250 mg and 500 mg.

ANI paid $11M in cash for the rights and existing inventory. It intends to launch the products under its own label in Q4 2014. The transaction will be immediately accretive and is expected to add $5.4M in revenues and $4M in non-GAAP EBITDA per year.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs